Potential Treatment for Early Polymyalgia Rheumatica (PMR)

This Phase 3 research study is evaluating an investigational study drug in adults with newly diagnosed or early relapsing polymyalgia rheumatica (PMR). The purpose of this study is to assess whether the investigational study drug affects PMR symptoms and steroid use in study participants. The investigational study drug is not approved by health authorities such as the US Food and Drug Administration (FDA) and is still under investigation for the treatment of PMR, so its effectiveness and safety have not been established. PMR is currently treated with corticosteroids like prednisone, which can cause side effects when used for long periods. This study is looking at whether an investigational study drug that targets inflammation associated with PMR may affect symptoms and steroid use. Intended for U.S. Audiences Only © 2026 Sanofi US Services, Inc. All Rights Reserved